Timing is everything! Appropriate timing of treatment is the key to successful intensive care; treatment that is delayed could be as detrimental as treatment that is premature. Th erefore, Lange and colleagues [1], in this issue of Critical Care, reported on the time course of the expression of the diff erent isoforms of the nitric oxide synthase (NOS) -that is, neuronal NOS [nNOS], inducible NOS [iNOS], and endothelial NOS [eNOS] (also known as NOS1, NOS2, and NOS3, respectively) -of the tissue levels of nitrotyrosine and poly(ADP-ribose), markers of nitrosative stress, and DNA damage resulting from peroxynitrite formation as well as p65, a mirror of the activation of the nuclear factor-kappa-B (NF-κB), in a well-established resuscitated ovine model of septic shock induced by Pseudomonas aeruginosa pneumonia.
'Downstream eff ects' were evaluated by measuring NOS activity, nitric oxide (NO) production, and interleukin-8 concentrations. During the early phase (that is, 4 to 12 hours after induction of pneumonia), eNOS expression was increased, and this coincided with increased tissue levels of nitrotyrosine, poly(ADP-ribose), and NF-κB activation, whereas in the later phase (that is, until 24 hours of pneumonia), measurable NOS activity and NO produc tion were related mainly to iNOS activation. Th e authors' 'two-hit' model of cotton smoke inhalation and subse quent instillation of live bacteria is characterized by a hyperdynamic circulation, hypo tension, tissue acidosis, and progressive impairment of gas exchange, lung mech anics, and morphological alterations typical of acute lung injury. Furthermore, the model comprises resuscitation measures and thus allows the study of pathophysiological pathways in a clinically relevant, large-animal setting.
Numerous studies evaluated the NO-related mediator orchestra and highlighted the friend-and-foe character of excess NO formation [2]: NO not only is well established as a reactive nitrogen species (RNS), often referred to as a 'fi nal mediator' of sepsis-induced hypotension, but also acts as a scavenger of reactive oxygen species (ROS), such as the superoxide radical. Th is reaction, however, leads to the formation of the even more toxic peroxynitrite, which ultimately results in protein nitrosylation, DNA damage, and activation of poly(ADP-ribose) polymerase (PARP) [3] . Finally, the NO production rate depends on the stimulus and the species, and therefore rodent data cannot be transferred directly to the clinical scenario [4] . Endogenous NO production in large animals is much closer to that of human beings, but although increased NO production during sepsis is well established [2], these models yielded controversial results [5] . Th e early and transient (within minutes) activation of PARP [3] would make PARP inhibition an attractive approach, but unfortunately medical care is usually not available during this very early phase. Moreover, the pathophysiological consequences of PARP-1 activation are opposed to its vital role in the maintenance of genomic integrity through its function in base excision repair, and the Abstract Appropriate timing of treatment assumes particular importance in critical care. Lange and colleagues recently reported on the time course of the diff erent nitric oxide synthase (NOS) isoforms, nitrosative stress, and poly(ADP-ribosylation) during Pseudomonas aeruginosa pneumonia-induced ovine septic shock. Initially, endothelial NOS expression was increased together with markers of peroxynitrite formation, DNA damage, and nuclear factor-kappa-B activation. Later on, measurable NOS activity and nitric oxide production resulted mainly from inducible NOS activation. These results emphasize the need for longterm, large-animal studies investigated over days so that future therapeutic interventions can be better tailored and matched to the exact time course of the activation of the mediator orchestra. [10] in rodents, and eNOS poly morphism was associated with hypotension during human Gramnegative sepsis [11] . Clearly, iNOS still seems to be a 'bad guy': several studies showed benefi cial eff ects of various selective iNOS inhibitors on hemo dynamics, lung function, deranged microcirculatory per fusion, coagulation disorders, and visceral organ injury [12] [13] [14] . Recent data, however, suggest that nNOS activation may also assume major importance [15] , and a combined approach using selective nNOS inhibition during the early phase (0 to 12 hours) and iNOS inhibi tion during the later phase (12 to 24 hours) yielded improved pulmonary function and attenuated nitrosative stress [16] . Finally, selective iNOS inhibition together with the ROS scavenger tempol also aff orded signifi cant protection, further emphasizing the close interaction of NO and oxidative/nitrosative stress [17] . Despite these encouraging results, nothing is simple or easy: in resuscitated murine septic shock, both genetic deletion and selective pharmacologic blockade of the iNOS were associated with markedly improved systolic contraction and catecholamine responsiveness but simultaneously deteriorated diastolic relaxation [18] . What can we learn from the study by Lange and colleagues [1]? Unfortunately, the authors did not report data on oxidative stress, so a complete overview of the whole RNS-and ROS-related mediator orchestra is only implicitly provided. Nevertheless, the authors add an important piece to the complex puzzle of the NO-related pathophysiological pathways: nitrosative stress (that is, increased nitrotyrosine and poly[ADP-ribose] levels) was aggravated only during the early phase up to 12 hours, whereas clear-cut increases in NOS activity, NO metabolites, and subsequently cytokines occurred only later on. Interestingly, in this experiment, in contrast to previous reports from the same group, nNOS synthesis was not increased. Finally, despite its inherent protective proper ties, eNOS activation was also involved in the initiation of the septic response, and it remains to be elucidated whether this mirrors an adaptive or pathologic mechanism.
How can we translate these data to daily care? Usually, there are few chances to intervene during the very early, evolving phase of sepsis and acute lung injury, and at the time of full-blown sepsis, all members of the mediator orchestra are already playing their (un)coordinated, and unfortunately sometimes uncontrollable, concert. Th ere are two ways to go from here, and both are worthy of being followed! First, though extremely time-and resource-consuming, long-or longer-term large-animal models with a more prolonged observation period (that is, days) are needed and will probably yield valuable clues to the design of clinical studies. Second, more studies on humans are warranted in order to better describe early and later phases of human sepsis in terms of NOS, peroxynitrite formation, and PARP activation. Th ese data might provide further evidence for drug and study design in the future. Lange and colleagues have the merit of having given the starting signal.
